Clinical Trials Logo

Clinical Trial Summary

To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with metastatic breast cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03730428
Study type Observational
Source Fudan University
Contact
Status Completed
Phase
Start date July 15, 2017
Completion date June 15, 2020

See also
  Status Clinical Trial Phase
Completed NCT02246361 - Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Phase 4
Completed NCT00997555 - Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients N/A
Recruiting NCT05280873 - Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP Phase 1
Completed NCT00081315 - Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer Phase 2
Active, not recruiting NCT04590547 - GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) Phase 2
Terminated NCT04370834 - Tocilizumab for Patients With Cancer and COVID-19 Disease Phase 2
Completed NCT02788643 - Study of Collagen IV and XIX in Bronchoalveolar Lavage, Pulmonary Aspiration and Bronchial Biopsies
Active, not recruiting NCT04326725 - Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia
Completed NCT03012958 - Utility of Lung Clearance Index Score as a Noninvasive Marker of Deployment Lung Disease
Completed NCT04721444 - Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence (COVID-19)
Terminated NCT04040244 - Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis N/A
Completed NCT04302688 - Accurate Classification System for Patients With COVID-19 Pneumonitis
Terminated NCT03962725 - Avoiding Neuromuscular Blockers to Reduce Complications Phase 4
Recruiting NCT05455034 - Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis Phase 1/Phase 2